- Home
- ATXS vs CBLL Comparison
ATXS vs CBLL Comparison
Compare ATXS & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- CBLL
- Stock Information
- Founded
- ATXS 2008
- CBLL 2014
- Country
- ATXS United States
- CBLL United States
- Employees
- ATXS N/A
- CBLL N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- CBLL
- Sector
- ATXS Health Care
- CBLL
- Exchange
- ATXS Nasdaq
- CBLL Nasdaq
- Market Cap
- ATXS 401.2M
- CBLL 433.7M
- IPO Year
- ATXS 2015
- CBLL 2024
- Fundamental
- Price
- ATXS $7.52
- CBLL $11.80
- Analyst Decision
- ATXS Buy
- CBLL Strong Buy
- Analyst Count
- ATXS 6
- CBLL 6
- Target Price
- ATXS $32.00
- CBLL $33.00
- AVG Volume (30 Days)
- ATXS 298.2K
- CBLL 318.0K
- Earning Date
- ATXS 08-12-2025
- CBLL 08-05-2025
- Dividend Yield
- ATXS N/A
- CBLL N/A
- EPS Growth
- ATXS N/A
- CBLL N/A
- EPS
- ATXS N/A
- CBLL N/A
- Revenue
- ATXS N/A
- CBLL $77,419,000.00
- Revenue This Year
- ATXS N/A
- CBLL $35.06
- Revenue Next Year
- ATXS N/A
- CBLL $28.56
- P/E Ratio
- ATXS N/A
- CBLL N/A
- Revenue Growth
- ATXS N/A
- CBLL 42.16
- 52 Week Low
- ATXS $3.56
- CBLL $10.01
- 52 Week High
- ATXS $12.92
- CBLL $32.75
- Technical
- Relative Strength Index (RSI)
- ATXS 64.14
- CBLL 41.37
- Support Level
- ATXS $6.50
- CBLL $11.18
- Resistance Level
- ATXS $6.82
- CBLL $12.05
- Average True Range (ATR)
- ATXS 0.44
- CBLL 0.54
- MACD
- ATXS 0.07
- CBLL 0.19
- Stochastic Oscillator
- ATXS 96.62
- CBLL 43.86
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About CBLL CeriBell Inc. Common Stock
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.